Cost-effectiveness: maximizing impact by meticulous data

In this issue of Blood, Yamamoto et al(1) report that treatment with first-line daratumumab in combination with bortezomib, thalidomide, and dexamethasone (Dara-VTd) or lenalidomide, bortezomib, dexamethasone (Dara-RVd) resulted in increased quality adjusted life years (QALYs) and lower costs compared with deferring daratumumab treatment to the second line in combination with carfilzomib and dexamethasone (Dara-Kd).

Automated summary

In this study, the first-line treatment with daratumumab in combination with different drugs was found to increase quality adjusted life years (QALYs) and reduce treatment costs compared to delaying daratumumab treatment and using it as a second-line therapy with carfilzomib and dexamethasone.